参附注射液治疗慢性心力衰竭的Meta分析  

Meta-analysis of Shenfu Injection in the Treatment of Chronic Heart Failure

作　　者：马敬[1] 叶玮[1] 郭建华[1] 张涛[1] 周莹[1] 丁婷[1] 张月瑜 费青青[1] 

机构地区：[1]同济大学附属东方医院,上海200123

出　　处：《湖北科技学院学报（医学版）》2017年第4期283-288,共6页Journal of Hubei University of Science and Technology(Medical Sciences)

摘　　要：目的评价参附注射液治疗慢性心力衰竭的功效。方法制定原始文献的纳入标准及检索策略,计算机检索中国期刊全文数据库、中国生物医学文献数据库、维普中文科技期刊全文数据库、万方医学及Pub Med数据库,提取有关慢性心力衰竭治疗的病例资料,观察组干预措施为参附注射液的随机对照研究(RCT)文献,评价纳入研究的文献质量,并提取有效数据后采用Rev Man5.3软件进行Meta分析。结果纳入研究19篇文献共有研究对象1829例:参附组928例;对照组901例。Meta分析结果显示:参附组与对照组临床有效率分别为91.49%、76.51%,OR值及其95%CI为3.38(2.47~4.61),差异有统计学意义(P<0.01)。生活质量表评分(MLHFQ)比较MD值-5.57(-8.26^-2.87),差异有统计学意义(P<0.01)。6min步行试验(6-MWT)比较MD值44.65(41.27~48.03),差异有统计学意义(P<0.01)。再次入院率为21.86%比37.64%,OR值及其95%CI为0.42(0.29~0.59),差异有统计学意义(P<0.05)。随访死亡率为4.37%比7.18%,OR值及其95%CI为0.59(0.31~1.13),差异无统计学意义(P>0.05)。结论参附注射液虽不能降低慢性心力衰竭的死亡率,但能明显提高生存期的生活质量,该疗法有推广价值。Objective To evaluate the effect of Shenfu injection in the treatment of chronic heart failure. Methods The inclusion criteria and retrieval strategies of the original documents were formulated. The data about the treatment of chronic heart failure were retrieved from the Chinese Journal Full-text Database,Chinese Biomedical Literature Database,Chinese Science Technology Periodical Full-text Database,Wanfang Medicine and Pub Med Database. The trial group was a randomized controlled study（ RCT） on the application of Shenfu injection for the treatment of chronic heart failure. The data were extracted and analyzed by Rev Man5. 3software. Results 1829 cases in 19 papers were included in this meta-analysis. There were 928 cases in the Shenfu group and there were 901 cases in the control group. The meta-analysis showed that the clinical effective rate of the Shenfu group and the control group was 91. 49% and 76. 51% respectively,and the OR value and its95% CI were 3. 38（ 2. 47 ～ 4. 61）,and P 0. 01. The difference was statistically significant. The MD of MLHFQ（ Minnesota Living With Heart Failure Questionnaire） was-5. 57（-8. 26 ～-2. 87）,P 0. 01 and the difference was statistically significant. The MD of 6-MWT was 44. 65（ 41. 27 ～ 48. 03）,P 0. 01 and the difference was statistically significant. The re-hospitalization rate was 21. 86% in the Shenfu group while in the control group,the ratio was 37. 64%. The OR value and 95% CI were 0. 42（ 0. 29 ～ 0. 59）,P 0. 05 and the difference was statistically significant. The follow-up mortality was 4. 37% in the Shenfu group while in the control group,the ratio was 7. 18%. The OR and 95% CI was 0. 59（ 0. 31 ～ 1. 13）,P 0. 05,the difference was not statistically significant. Conclusion Shenfu injection is unable to reduce the mortality of chronic heart failure,but it can significantly improve the quality of life significantly.

关 键 词：参附注射液 慢性心力衰竭 META分析 

分 类 号：R541.6[医药卫生—心血管疾病]